Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS,APS nephropathy and heart valve lesions
Restricted accessResearch articleFirst published online February, 2011
Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS,APS nephropathy and heart valve lesions
The objectives of the ‘Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations’ were to assess the clinical utility of the international consensus statement on classification criteria and treatment guidelines for the catastrophic APS, to identify and grade the studies that analyse the relationship between the antiphospholipid antibodies and the non-criteria APS manifestations and to present the current evidence regarding the accuracy of these non-criteria APS manifestations for the detection of patients with APS. This article summarizes the studies analysed on the catastrophic APS, APS nephropathy and heart valve lesions, and presents the recommendations elaborated by the Task Force after this analysis.
CerveraR. on behalf of the ‘CAPS Registry Project Group’. Catastrophic antiphospholipid syndrome (CAPS): update from the ‘CAPS Registry’. Lupus2010; 19: 412–418.
2.
CerveraRPietteJCFontJ. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum2002; 46: 1019–1027.
3.
AshersonRACerveraRde GrootPR. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus2003; 12: 530–534.
4.
AshersonRAEspinosaGCerveraR. Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. Ann Rheum Dis2005; 64 : 943–946.
5.
ErkanDAshersonRAEspinosaG. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis2003; 62: 530–533.
6.
BayraktarUDErkanDBucciarelliSEspinosaGAshersonRA, for the Catastrophic Antiphospholipid Syndrome Project Group. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol2007; 34: 346–352.
7.
CerveraRBucciarelliSPlasínMA. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the ‘CAPS Registry’. J Autoimmun2009; 32: 240–245.
8.
AshersonREspinosaGMenahenS. Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum2008; 37: 366–372.
9.
CerveraRFontJGómez-PuertaJA. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis2005; 64: 1205–1209.
BucciarelliSEspinosaGCerveraR. Mortality in catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum2006; 54: 2568–2576.
12.
Kincaid-SmithPFairleyKFKlossM. Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure. Q J Med1988; 68: 795–815.
13.
KleinknechtDBobrieGMeyerONoëlLHCallardPRamdaneM. Recurrent thrombosis and renal vascular disease in patients with a lupus anticoagulant. Nephrol Dial Transplant1989; 4: 854–858.
14.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
NochyDDaugasEDrozD. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol1999; 10: 507– 518.
17.
DaugasENochyDHuong duLT. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol2002; 13: 42–52.
18.
TektonidouMGSotsiouFMoutsopoulosHM. Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary and systemic lupus erythematosus-related APS. J Rheumatol2008; 35: 1983–1988.
19.
D’AgatiVKunisCWilliamsGAppelGB. Anticardiolipin antibody and renal disease: a report of three cases. J Am Soc Nephrol1990; 1: 777–784.
20.
SokunbiDOMillerFWadhwaNKNordEP. Reversible renal failure in the primary antiphospholipid syndrome – a report of two cases. J Am Soc Nephrol1993; 4: 28–35.
21.
FakhouriFNoelLHZuberJ. The expanding spectrum of renal diseases associated with antiphospholipid syndrome. Am J Kidney Dis2003; 41: 1205–1211.
22.
TektonidouMGSotsiouFNakopoulouLVlachoyiannopoulosPGMoutsopoulosHM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum2004; 50: 2569–2579.
23.
LeakerBMcGregorAGriffithsMSnaithMNeildGHIsenbergD. Insidious loss of renal function in patients with anticardiolipin antibodies and absence of overt nephritis. Br J Rheumatol1991; 30: 422–425.
24.
CacoubPWechslerBPietteJC. Malignant hypertension in antiphospholipid syndrome without overt lupus nephritis. Clin Exp Rheumatol1993; 11: 479–485.
25.
HughsonMDMcCartyGABrumbackRA. Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. Hum Pathol1995; 26: 716–724.
26.
MossKEIsenbergDA. Comparison of renal disease severity and outcome in patients with primary antiphospholipid syndrome, antiphospholipid syndrome secondary to systemic lupus erythematosus (SLE) and SLE alone. Rheumatology (Oxford)2001; 40: 863–867.
27.
FarrugiaETorresVEGastineauDMichetCJHolleyKE. Lupus anticoagulant in systemic lupus erythematosus: a clinical and renal pathological study. Am J Kidney Dis1992; 20: 463–471.
28.
BandariSHarndenPBrownjohnAMTurneyJH. Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis. QJM1998; 91: 401–409.
29.
MirandaJMGarcia-TorresRJaraLJ. Renal biopsy in systemic lupus erythematosus: significance of glomerular thrombosis. Analysis of 108 cases. Lupus1994; 3: 25–29.
30.
NaikerIPRughubarKNDuursmaJPudifinDJSeedatYK. Anticardiolipin antibodies in South African patients with lupus nephritis: a clinical and renal pathological study. Am J Nephrol2000; 20: 351–357.
31.
KantKSPollakVEWeissMAGlueckHIMillerMAHessEV. Glomerular thrombosis in systemic lupus erythematosus. Prevalence and significance. Medicine1981; 60: 71–86.
32.
GlueckHIKantKSWeissMAPollakVEMillerMACootsM. Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants. Arch Intern Med1985; 145: 1389–1395.
33.
SilbigerJJ. The cardiac manifestations of antiphospholipid syndrome and their echocardiographic recognition. J Am Soc Echocardiogr2009; 22: 1100–1108.
34.
KhamashtaMACerveraRAshersonRA. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet1990; 335: 1541–1544.
35.
NyhoyannopoulosPGomezPMJoshiJLoizouSWalportMJOakleyCM. Cardiac abnormalities in systemic lupus erythematosus: association with raised anticardiolipin antibodies. Circulation1990; 82: 369–375.
36.
LeungWHWongKLLauCPWongCKLiuHW. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med1990; 89: 411–419.
37.
CerveraRFontJParéC. Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis1992; 51: 156–159.
38.
RoldanCAShivelyBKLauCCGuruleFTSmithEACrawfordMH. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol1992; 20: 1127–1134.
39.
JouhikainenTPohjola-SintonenSStephanssonE. Lupus anticoagulant and cardiac manifestations in systemic lupus erythematosus. Lupus1994; 3: 167–172.
40.
GabrielliFAlciniEDi PrimaMAMazzacuratiGMasalaC. Cardiac valve involvement in systemic lupus erythematosus and primary antiphospholipid syndrome: lack of correlation with antiphospholipid antibodies. Int J Cardiol1995; 51: 117–126.
41.
OmdalRLundePRasmussenKMellgrenSIHusbyG. Transesophageal and transthoracic echocardiography and Doppler-examinations in systemic lupus erythematosus. Scand J Rheumatol2001; 30: 275–281.
42.
LeszczynskiPStraburzynska-MigalEKorczowskaILackiJKMackiewiczS. Cardiac valvular disease in patients with systemic lupus erythematosus. Relationship with anticardiolipin antibodies. Clin Rheumatol2003; 22: 405–408.
43.
Perez-VillaFFontJAzquetaM. Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, follow up study. Arthritis Care Res2005; 53: 460–467.
44.
RoldanCAGelgandEAQuallsCRSibbittWL. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol2005; 95: 1441–1447.
45.
AmorosoACacciapagliaFDe CastroS. The adjunctive role of antiphospholipid antibodies in systemic lupus erythematosus cardiac involvement. Clin Exp Rheumatol2006; 24: 287–294.
46.
Farzaneh-FarRomanMJLockshinMD. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum2006; 54: 3918–3925.
47.
RoldanCAGelgandEAQuallsCRSibbittWL. Valvular heart disease by transthoracic echocardiography is associated with focal brain injury and central neuropsychiatric systemic lupus erythematosus. Cardiology2007; 108: 331–337.
48.
NesherGIlanyJRosenmannDAbrahamAS. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum1997; 27: 27–35.
49.
BrennerBBlumefeldZMarkiewiczWReisnerSA. Cardiac involvement in patients with primary antiphospholipid syndrome. J Am Coll Cardiol1991; 18: 931–936.
50.
CerveraRKhamashtaMAFontJ. High prevalence of significant heart valve lesions in patients with the ‘primary’ antiphospholipid syndrome. Lupus1991; 1: 43–47.
51.
GalveEOrdiJBarquineroJEvangelistaAVilardellMSoler-SolerJ. Valvular heart disease in the primary antiphospholipid syndrome. Ann Intern Med1992; 116: 293–298.
52.
BadiuESolorioSMartinezE. The heart in the primary antiphospholipid syndrome. Arch Med Res1995; 26: 115–120.
53.
García-TorresRAmigoMCde la RosaAMorónAReyesPA. Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings. Lupus1996; 5: 56–61.
54.
Espínola-ZavaletaNVargas-BarronJComenares-GalvisT. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am Heart J1999; 137: 973–979.
TurielMMuzzupappaSGottardiBCremaCSarzi-PuttiniPRossiE. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus2000; 9: 406–412.
57.
ErdoganDGorenMTDiz-KucukkayaRInancM. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study. Stroke2005; 36: 592–596.
58.
TurielMSarzi-PuttiniPPerettiR. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol2005; 96: 574–579.
59.
GleasonCBStoddardMFWagnerSGLongakerRAPierangeliSHarrisEN. A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin-negative systemic lupus erythematosus. Am Heart J1993; 125: 1123–1129.
60.
ViannaJLKhamashtaMAOrdi-RosJ. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med1994; 96: 3–9.
61.
KrauseILevSFraserA. Close association between valvular heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis2005; 64: 1490–1493.
62.
Pardos-GeaJOrdi-RosJAveglianoG. Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients. Lupus2010; 19: 575–582.
63.
GuzmanLThumalaA. Severe mitral valvular disease in systemic lupus erythematosus. Lupus1995; 4: 79–79.
64.
ShahianDMLabibSBSchneebaumAB. Ethiology and management of chronic valve disease in antiphospholipid antibody syndrome and systemic lupus erythematosus. J Card Surg1995; 10: 133–139.
65.
LockshinMTenediosFPetriM. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus2003; 12: 518–523.
